Harvard Bioscience, Inc. (HBIO)
Nasdaq · Healthcare · Medical Instruments & Supplies
$8.50+1.92%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $38.7M
- Forward P/E
- 13.2
- 52-week range
- $3.80 – $9.40
- 52-week change
- +89.55%
- EPS (trailing)
- −$2.31
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $86.5M (−8.06%)
- Net income
- −$56.7M
- Operating margin
- −56.1%
- Diluted EPS
- −$1.28
- Free cash flow
- $5.5M
From the company’s annual report on SEC EDGAR.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
Headquarters: Holliston, United States · 316 employees · harvardbioscience.com